Trecator
(Ethionamide)Phase 2Small molecule
Trecator is one of 34 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
33
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Pulmonary Tuberculosis
#DrugCompanyPhaseTrials
1Priftin
SanofiApproved
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Myambutol
VVA Greater Los Angeles Healthcare System
Approved
Calciferol
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Tuberculosis1 trial
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled
NAC1 trial
Phase 21 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
TRECATOR
NDA NDA013026
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ethionamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- WWyeth-Lederle Vaccines